AAIC Day One 2026 Highlights

Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC.

Series closer, and the relay comes full circle: Carla Abdelnour, who hosted episode one, returns as the guest. Carla is a clinician scientist in Barcelona and incoming Chair of the ISTAART Clinical Trials Advancement and Methods PIA, working on mixed neurodegenerative disease, particularly Lewy body and Alzheimer's pathology together. With host Sindhuja Tirumalai Govindarajan she explains why co-pathology is so common and what it means for treatment: does someone with both alpha-synuclein and Alzheimer's pathology respond to an anti-amyloid drug the same way as someone without? They discuss why she leans on fluid biomarkers, the wish for a synuclein PET tracer, and how trials might stratify or include people by co-pathology. Carla makes a useful point for anyone designing research, that clinical trial methods translate straight to observational studies, and previews the CTAM PIA's AAIC programme, including a panel and featured session on global representation in trials.

Takeaways

• Mixed pathology is common, and co-occurring alpha-synuclein and Alzheimer's pathology may change how people respond to treatment.
• Trials could stratify or include people by co-pathology, but alpha-synuclein is currently detectable only in CSF, which limits that.
• Fluid biomarkers offer the specificity to track different proteinopathies and, potentially, response to treatment.
• Clinical trial design transfers straight to observational research: the same inclusion criteria, outcomes and sample-size thinking.
• Global representation in trials is a live priority, with a CTAM panel launching at AAIC.

--

The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests.

There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between.

Find out more at https://istaart.alz.org/

--

A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk.

If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website.

Leave us a tip:

https://dementia-researcher.captivate.fm/support

Follow us on social media:

• https://www.instagram.com/dementia_researcher/
• https://www.facebook.com/Dementia.Researcher/
• https://www.twitter.com/demrescommunity
• https://www.linkedin.com/company/dementia-researcher
• https://bsky.app/profile/dementiaresearcher.bsky.social

Download and Register with our Community App:

https://www.onelink.to/dementiaresearcher

We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research.

The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors.

Subscribe to our sister show 'Dementia Rese...